Nucryst’s anti-eczema cream starts Phase 2

Dec. 4, 2003 — Nucryst Pharmaceuticals Corp. has begun Phase 2 clinical trials of a topical cream formulation of its nanocrystalline silver for a form of eczema and other skin conditions, according to a news release.


The subsidiary of Canada-based Westaim Corp. said the yearlong study involves 20 clinical sites and 1,180 patients across the United States. Laboratory studies have shown that nanosilver can be used to counter microbes and inflammation, the release said.


Nucryst said its first product, a nanosilver-based burn dressing called Acticoat sold and distributed by wound treatment supplier Smith & Nephew, is profitable.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.